Xoma Royalty

Xoma Royalty company information, Employees & Contact Information

Explore related pages

Related company profiles:

XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

Company Details

Employees
128
Founded
-
Address
2200 Powell Street,
Phone
510-204-7200
Email
Bi****@****oma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
xoma.com
HQ
Emeryville, California
Looking for a particular Xoma Royalty employee's phone or email?

Xoma Royalty Questions

News

XOMA Royalty Corporation Extends Tender Offer for LAVA Therapeutics Shares Until October 17, 2025 - Quiver Quantitative

XOMA Royalty Corporation Extends Tender Offer for LAVA Therapeutics Shares Until October 17, 2025 Quiver Quantitative

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. - Yahoo Finance

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. Yahoo Finance

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference - The Manila Times

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference The Manila Times

XOMA Royalty Declares Quarterly Preferred Stock Dividends - Yahoo Finance

XOMA Royalty Declares Quarterly Preferred Stock Dividends Yahoo Finance

XOMA Royalty Corporation Executives to Present Company Update at H.C. Wainwright 27th Annual Global Investment Conference - Quiver Quantitative

XOMA Royalty Corporation Executives to Present Company Update at H.C. Wainwright 27th Annual Global Investment Conference Quiver Quantitative

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference - FinancialContent

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference FinancialContent

XOMA Royalty Corporation Declares Cash Dividends for Series A and Series B Preferred Stock - Quiver Quantitative

XOMA Royalty Corporation Declares Cash Dividends for Series A and Series B Preferred Stock Quiver Quantitative

XOMA Royalty Completes Sale of Kinnate Pipeline Assets - GlobeNewswire

XOMA Royalty Completes Sale of Kinnate Pipeline Assets GlobeNewswire

Inside INdiana Business - FinancialContent

Inside INdiana Business FinancialContent

XOMA Royalty Reports Second Quarter and Year to Date 2025 - GlobeNewswire

XOMA Royalty Reports Second Quarter and Year to Date 2025 GlobeNewswire

XOMA Corporation Announces Closing of Tender Offer - GlobeNewswire

XOMA Corporation Announces Closing of Tender Offer GlobeNewswire

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements - GlobeNewswire

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements GlobeNewswire

XOMA Royalty Corporation Completes Tender Offer for HilleVax, Inc. Shares and Merger Finalized - Quiver Quantitative

XOMA Royalty Corporation Completes Tender Offer for HilleVax, Inc. Shares and Merger Finalized Quiver Quantitative

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements - Yahoo Finance

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements Yahoo Finance

ESSA Pharma to be Acquired by XenoTherapeutics, Backed by XOMA Royalty - citybiz

ESSA Pharma to be Acquired by XenoTherapeutics, Backed by XOMA Royalty citybiz

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million - GlobeNewswire

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million GlobeNewswire

Turnstone Biologics Corp. Enters into Agreement to be - GlobeNewswire

Turnstone Biologics Corp. Enters into Agreement to be GlobeNewswire

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction - Yahoo Finance

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction Yahoo Finance

XOMA Royalty Significantly Expands its Royalty and - GlobeNewswire

XOMA Royalty Significantly Expands its Royalty and GlobeNewswire

XOMA Royalty Completes Tender Offer for Turnstone Biologics, Stockholders to Receive Cash and Contingent Value Right - Quiver Quantitative

XOMA Royalty Completes Tender Offer for Turnstone Biologics, Stockholders to Receive Cash and Contingent Value Right Quiver Quantitative

77.5% Shareholders Accept: XOMA Royalty Acquires Biotech HilleVax in Cash-Plus-CVR Deal Worth $1.95/Share - Stock Titan

77.5% Shareholders Accept: XOMA Royalty Acquires Biotech HilleVax in Cash-Plus-CVR Deal Worth $1.95/Share Stock Titan

XOMA Royalty Acquires Pulmokine, Adding Seralutinib as its Seventh Phase 3 Royalty Asset - Quiver Quantitative

XOMA Royalty Acquires Pulmokine, Adding Seralutinib as its Seventh Phase 3 Royalty Asset Quiver Quantitative

XOMA Royalty Expands Biotech Portfolio: Acquires HilleVax in Cash Plus CVR Deal Worth Over $1.95 Per Share - Stock Titan

XOMA Royalty Expands Biotech Portfolio: Acquires HilleVax in Cash Plus CVR Deal Worth Over $1.95 Per Share Stock Titan

$1.04 per share: XOMA Royalty & LAVA amend purchase agreement, add up to $0.23 CVR - Stock Titan

$1.04 per share: XOMA Royalty & LAVA amend purchase agreement, add up to $0.23 CVR Stock Titan

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) - Yahoo Finance

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) Yahoo Finance

XOMA Royalty Acquires Pulmokine for $20 Million Adding the - GlobeNewswire

XOMA Royalty Acquires Pulmokine for $20 Million Adding the GlobeNewswire

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition - GlobeNewswire

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition GlobeNewswire

98% Premium: XOMA Royalty Acquires Cancer Drug Developer Mural Oncology in $36.2M Strategic Deal - Stock Titan

98% Premium: XOMA Royalty Acquires Cancer Drug Developer Mural Oncology in $36.2M Strategic Deal Stock Titan

XOMA Raises up to $140 Million in Non-Dilutive, - GlobeNewswire

XOMA Raises up to $140 Million in Non-Dilutive, GlobeNewswire

Press Release: XOMA Royalty Declares Quarterly Preferred Stock Dividends - 富途牛牛

Press Release: XOMA Royalty Declares Quarterly Preferred Stock Dividends 富途牛牛

Inside INdiana Business - FinancialContent

Inside INdiana Business FinancialContent

XOMA to Present at 43rd Annual Cowen Health Care Conference - Stock Titan

XOMA to Present at 43rd Annual Cowen Health Care Conference Stock Titan

XOMA Declares Quarterly Preferred Stock Dividends - FinancialContent

XOMA Declares Quarterly Preferred Stock Dividends FinancialContent

XOMA Corporation Announces Closing of Tender Offer - FinancialContent

XOMA Corporation Announces Closing of Tender Offer FinancialContent

ESSA Pharma Shareholders to Receive $1.91 Cash Plus CVR in XenoTherapeutics Acquisition Deal - Stock Titan

ESSA Pharma Shareholders to Receive $1.91 Cash Plus CVR in XenoTherapeutics Acquisition Deal Stock Titan

XOMA Enters into Agreement to Acquire Kinnate Biopharma for - GlobeNewswire

XOMA Enters into Agreement to Acquire Kinnate Biopharma for GlobeNewswire

XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program - GlobeNewswire

XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program GlobeNewswire

XOMA Declares Quarterly Preferred Stock Dividends - FinancialContent

XOMA Declares Quarterly Preferred Stock Dividends FinancialContent

Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement - GlobeNewswire

Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement GlobeNewswire

Results From Two Phase 2 Studies in XOMA's Gevokizumab - GlobeNewswire

Results From Two Phase 2 Studies in XOMA's Gevokizumab GlobeNewswire

Photo Release -- XOMA Appoints John Varian as Chief Executive Officer - GlobeNewswire

Photo Release -- XOMA Appoints John Varian as Chief Executive Officer GlobeNewswire

It’s Alive! Meet One of Biotech’s Zombies (Published 2007) - The New York Times

It’s Alive! Meet One of Biotech’s Zombies (Published 2007) The New York Times

XOMA Reports Third Quarter 2006 Results - GlobeNewswire

XOMA Reports Third Quarter 2006 Results GlobeNewswire

Top Xoma Royalty Employees

  • Thomas Burns

    Thomas Burns

    n/a

    San Rafael, California, United States, United States
    4
    xoma.com, gmail.com, gmail.com, xoma.com

    3 +151020XXXXX

  • Joyce Chan

    Joyce Chan

    n/a

    San Francisco Bay Area, United States
    2
    amgen.com, xoma.com
  • Barbara Kosacz

    Barbara Kosacz

    n/a

    Los Altos, California, United States, United States
    4
    cooley.com, sbcglobal.net, cooley.com, kronosbio.com

    4 +165082XXXXX

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant